NASDAQ · RCEL
Avita Medical Inc.
$16.71+$0.21 (+1.27%)
Avita Medical Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.12% below the high.
Loading market information…
AMEX · XTNT · USD
Stock price, earnings
Quote as of Oct 29, 2026, 07:59 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Xtant Medical Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 69.43% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Xtant Medical Holdings, Inc.’s next earnings report is currently expected on Nov 10, 2026, with estimated earnings per share of -$0.03. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Xtant Medical Holdings, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Xtant Medical Holdings, Inc., a company based in Belgrade, Montana, specializes in the development, production, and distribution of advanced regenerative medicine products and medical devices. The firm primarily serves orthopedic and neurological surgeons both within the United States and globally. Its comprehensive product portfolio is categorized into several key areas: 1. Biomaterial Offerings: This category includes products like OsteoSponge, which provides a natural structural support for cellular growth and introduces vital bone-forming proteins to aid the healing process. OsteoSponge SC is specifically designed to repair bone defects in the subchondral area of joints. Other items are OsteoSelect DBM Putty, fostering osteoinductive bone regeneration, and OsteoSelect PLUS DBM Putty, which functions as a bone void filler and graft substitute for procedures involving the pelvis, extremities, and posterolateral spine. Additionally, the line features OsteoFactor, containing diverse proteins and peptides that facilitate bone formation and remodeling, along with OsteoWrap and OsteoVive Plus, a cellular bone matrix enriched with growth factors. 2. Allograft Technologies: Under the 3Demin brand, Xtant Medical provides a range of allografts (human bone grafts) engineered to maximize both osteoconductivity and osteoinductive capabilities. This includes specialized sports allografts used for repairing anterior and posterior cruciate ligaments, ACL reconstruction, and meniscal repairs. They also offer milled spinal allografts, where cortical bone is precisely shaped to specific dimensions, as well as traditional allografts applicable across numerous medical disciplines such such as orthopedics, neurology, podiatry, oral/maxillofacial surgery, genitourinary, and plastic/reconstructive surgery. 3. Spinal Fixation and Fusion Systems: The company furnishes a variety of sophisticated spinal devices. These include the Certex spinal fixation system, Spider cervical plating, Axle interspinous fusion, Silex Sacroiliac joint fusion, the Xpress minimally invasive pedicle screw system, and Fortex Pedicle screw systems. Further systems encompass Calix, for use in cervical and thoracolumbar regions, the Axle-X interspinous fusion system, Irix-C for cervical integrated fusion, and the Irix-A Lumbar integrated fusion system. The company underwent a name change in July 2015, transitioning from its former identity as Bacterin International Holdings, Inc. to Xtant Medical Holdings, Inc.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:09 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 12, 2025 | $0.00+104.0% vs estimate | $32.90M+5.39% vs estimate |
|---|
| Q4 2024 | Mar 6, 2025 | -$0.02-100.0% vs estimate | $31.51M-0.89% vs estimate |
|---|
| Q3 2024 | Nov 12, 2024 | -$0.04-60.0% vs estimate | $27.94M-12.13% vs estimate |
|---|
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
THE ANALYST VIEW
5 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $1.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$16.71+$0.21 (+1.27%)
Avita Medical Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.12% below the high.
$3.65$0.00 (0.0%)
Quipt Home Medical Corp.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$19.09$0.00 (0.0%)
Fonar Corp.’s quoted price sits in the upper half of its reported 52-week range, 0.34% below the high.
$2.69+$0.08 (+3.07%)
Apyx Medical Corporation’s quoted price sits in the lower half of its reported 52-week range, 47.05% below the high.
$1.14$0.00 (0.0%)
Vivani Medical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 36.67% below the high.
$0.43+$0.02 (+5.03%)
Lucid Diagnostics Inc.’s quoted price sits in the lower half of its reported 52-week range, 73.48% below the high.
$4.11-$0.12 (-2.72%)
eXoZymes, Inc.’s quoted price sits in the lower half of its reported 52-week range, 77.66% below the high.
$0.79-$0.01 (-1.38%)
Rapid Micro Biosystems, Inc.’s quoted price sits in the lower half of its reported 52-week range, 84.03% below the high.
